10-QPeriod: Q1 FY2008

THERMO FISHER SCIENTIFIC INC. Quarterly Report for Q1 Ended Mar 29, 2008

Filed May 2, 2008For Securities:TMO

Summary

Thermo Fisher Scientific Inc. reported solid financial results for the first quarter of 2008, demonstrating strong revenue growth and improved profitability. Consolidated revenues increased by 9% year-over-year to $2.55 billion, driven by robust performance in both the Analytical Technologies and Laboratory Products and Services segments. This top-line growth was complemented by a significant improvement in operating income, which rose 51% to $290.4 million, leading to a substantial increase in diluted earnings per share from $0.31 to $0.53. The company's operational efficiency gains, integration savings from prior acquisitions, and strategic pricing actions contributed to margin expansion. Despite ongoing investments in acquisitions and capital expenditures, Thermo Fisher maintained a healthy cash flow from operations, which increased to $243 million. The company's liquidity position remains strong, supported by substantial cash reserves and available borrowing capacity, indicating financial stability and the ability to fund ongoing operations and strategic initiatives.

Key Highlights

  • 1Consolidated revenues for the first quarter of 2008 increased 9% to $2.55 billion, up from $2.34 billion in the prior year period.
  • 2Operating income saw a significant increase of 51% year-over-year, reaching $290.4 million in Q1 2008, compared to $192.4 million in Q1 2007.
  • 3Diluted Earnings Per Share (EPS) from continuing operations grew to $0.54 in Q1 2008, up from $0.31 in Q1 2007.
  • 4The Analytical Technologies segment reported a 10% revenue increase to $1.09 billion, with an operating income margin of 21.0%.
  • 5The Laboratory Products and Services segment's revenue rose 9% to $1.57 billion, and its operating income margin improved to 13.9%.
  • 6Cash flow from operating activities increased to $243.0 million in Q1 2008 from $218.6 million in Q1 2007, indicating strong operational cash generation.
  • 7The company repurchased $102 million of its common stock during the quarter, demonstrating a commitment to returning value to shareholders.

Frequently Asked Questions

Revenue growth was driven by increased demand for products and services across both the Analytical Technologies and Laboratory Products and Services segments. Strategic acquisitions, favorable currency translation effects, and price increases also contributed to the overall revenue increase.

Profitability was enhanced through higher gross margins from incremental revenues, successful integration savings from past mergers, productivity improvements such as better material sourcing, and lower operating costs following restructuring actions. A significant factor was also a reduction in restructuring and other costs compared to the prior year's first quarter.

Thermo Fisher Scientific maintained a strong liquidity position with $734.0 million in cash and cash equivalents as of March 29, 2008. The company had $2.20 billion in outstanding debt, with the majority due in 2010 and beyond. They believe their current cash, future operating cash flow, and available borrowing capacity are sufficient to meet working capital requirements for at least the next 24 months.

Key risks include intense competition and technological changes requiring continuous product innovation, potential difficulties in integrating acquired businesses and realizing anticipated synergies, risks related to protecting intellectual property, reliance on customer capital spending and government funding, general economic conditions, and potential fluctuations in currency exchange rates due to their significant international operations.